Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$0.12	$0.16	$0.09 ▼ $3.39	$997K	-0.06	182,361 shs	18,611 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
PTPI Petros Pharmaceuticals	$0.03 -1.8%	$0.03	$0.02 ▼ $16.25	$857K	1.56	4.98 million shs	260,246 shs
TCBP TC Biopharm	$0.68 -55.8%	$0.68	$0.50 ▼ $160.00	$279K	0.01	177,918 shs	5.33 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	0.00%	-7.83%	-22.58%	-33.33%	-92.00%
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%
PTPI Petros Pharmaceuticals	0.00%	-10.13%	-8.03%	-29.49%	-99.68%
TCBP TC Biopharm	0.00%	0.00%	0.00%	0.00%	-99.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPTH Bio-Path	0.8774 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	1.3
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCBP TC Biopharm	1.5341 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTH Bio-Path	0.00	N/A	N/A	N/A
NMTR 9 Meters Biopharma	0.00	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	0.00	N/A	N/A	N/A
TCBP TC Biopharm	3.00	Buy	$48.00	6,948.46% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.17	N/A	N/A	$4.04 per share	0.01
TCBP TC Biopharm	$4.76M	0.06	N/A	N/A	$519.58 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTH Bio-Path	-$16.08M	N/A	0.00	N/A	N/A	N/A	-2,842.40%	-337.48%	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
PTPI Petros Pharmaceuticals	-$8.16M	-$52.91	N/A	∞	N/A	N/A	-78.22%	-23.50%	N/A
TCBP TC Biopharm	-$7.35M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCBP TC Biopharm	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTH Bio-Path	N/A	0.86	0.86
NMTR 9 Meters Biopharma	N/A	0.59	0.59
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
TCBP TC Biopharm	0.67	1.12	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPTH Bio-Path	5.74%
NMTR 9 Meters Biopharma	22.34%
PTPI Petros Pharmaceuticals	12.34%
TCBP TC Biopharm	16.25%

Insider Ownership

Company	Insider Ownership
BPTH Bio-Path	0.72%
NMTR 9 Meters Biopharma	2.40%
PTPI Petros Pharmaceuticals	12.25%
TCBP TC Biopharm	15.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTH Bio-Path	10	8.31 million	5.73 million	Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
TCBP TC Biopharm	80	410,000	28,000	Not Optionable

TCBP, BPTH, NMTR, and PTPI Headlines

Recent News About These Companies

Who is Bryan Kobel? Biotech CEO sues Uber after viral driver assault video

August 22 at 8:43 AM | msn.com

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

June 11, 2025 | prnewswire.com

TC BioPharm Holdings PLC (TCBPY)

May 11, 2025 | investing.com

TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells

April 9, 2025 | finance.yahoo.com

TC BioPharm: TCBP Announces Transition from Nasdaq to OTC Markets

March 24, 2025 | finanznachrichten.de

TC BioPharm to be delisted from Nasdaq, moves to OTC Markets

March 23, 2025 | uk.investing.com

TC Biopharm announces transition to OTC Markets from Nasdaq

March 22, 2025 | markets.businessinsider.com

TC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses Frustration

March 21, 2025 | msn.com

TC BioPharm Transitions from Nasdaq to OTC Markets Amid Delisting Notice

March 21, 2025 | tipranks.com

TCBP Announces Transition from Nasdaq to OTC Markets

March 21, 2025 | prnewswire.com

TC Biopharm launches cost reduction initiatives

March 19, 2025 | finance.yahoo.com

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

March 18, 2025 | prnewswire.com

TC BioPharm: TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

March 5, 2025 | finanznachrichten.de

TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

March 5, 2025 | prnewswire.com

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week

February 28, 2025 | msn.com

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

February 20, 2025 | prnewswire.com

TC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

February 13, 2025 | finanznachrichten.de

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

February 13, 2025 | prnewswire.com

TC BioPharm: TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

February 11, 2025 | finanznachrichten.de

TC Falls Despite Cohort B Trials

February 11, 2025 | baystreet.ca

New MarketBeat Followers Over Time

TCBP, BPTH, NMTR, and PTPI Company Descriptions

Bio-Path NASDAQ:BPTH

$0.12 0.00 (0.00%)

As of 08/22/2025 03:00 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-1.79%)

As of 08/22/2025 03:54 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

TC Biopharm NASDAQ:TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time